Price Performance & Valuation Year to date, GSK’s stock has gained 4.8% compared to the industry’s 20.0% growth. The stock has also underperformed the sector and the S&P 500.

GSK and S&P 500 Performance During 2007-08 Crisis GSK stock declined from $53 in September 2007 (pre-crisis peak) to around $28 in March 2009, as the markets bottomed out, implying it lost 48% of ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

For new and old investors, taking full advantage of the stock market and investing with confidence are ... which is more than double the S&P 500's performance over the same time frame. However, the ...

Consequently, GSK will be exempted from these cases, alleviating the need for further pre-trial hearings. Also Read: GSK Upgrades Long-Term Outlook After Q4 Performance, Shingrix Vaccine And Newly ...

GSK is a Zacks Rank #3 (Hold) stock, with a Value Style Score of A and VGM Score of B. Shares are currently trading at a forward P/E of 9.2X for the current fiscal year compared to the Medical ...

GlaxoSmithKline Is Moving Forward After Woeful Performance Jul. 08, 2014 5:27 PM ET GSK plc (GSK) Stock AZN, MRK, NVS PFE INVA GSK 8 Comments Options Calling 480 Follower s ...

The stock holds a P/E ratio of 12.69, while its industry has an average P/E of 14.35. GSK's Forward P/E has been as high as 14.45 and as low as 11.02, with a median of 12.77, all within the past year.

Price Performance & Valuation Year to date, GSK’s stock has gained 4.8% compared to the industry ’s 20.0% growth. The stock has also underperformed the sector and the S&P 500.

GSK and S&P 500 Performance During 2007-08 Crisis GSK stock declined from $53 in September 2007 (pre-crisis peak) to around $28 in March 2009, as the markets bottomed out, implying it lost 48% of ...